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Sulfadoxine-pyrimethamine (SP) remains widely recommended for intermittent preventive treatment
against Plasmodium falciparum malaria for pregnant women and infants in Africa. Resistance to SP is
increasing and associated primarily with mutations in the P. falciparum dhfr (Pfdhfr) and Pfdhps genes. This
study aimed to explore the hypothetical association of genetic alterations in the P. falciparum multidrug
resistance protein gene (Pfmrp1) with the in vivo response to SP by detecting the selection of single nucleotide
polymorphisms (SNPs) following standard single-dose treatment administered to children with acute uncom-
plicated P. falciparum malaria in Tanzania. We detected significant selection of parasites carrying the Pfmrp1
1466K allele in samples from children with recrudescent infections, with 12 (100%) of 12 such samples being
positive for this allele, compared to 52 (67.5%) of 77 baseline samples (P  0.017), in parallel with the selection
of the Pfdhfr Pfdhps quintuple mutant haplotype in cases of recrudescence (P  0.001). There was no
association between the 1466K SNP and the Pfdhfr Pfdhps quintuple mutation, indicating independent selec-
tions. Our data point for the first time to a role for a P. falciparum multidrug resistance protein homologue in
the antimalarial activity of SP. Moreover, they add to the growing evidence of the potential importance of
Pfmrp1 in antimalarial drug resistance.
The antifolate drug formulation sulfadoxine-pyrimethamine
(SP) is still globally used, either as monotherapy or in combi-
nation with other antimalarials (http://www.who.int/malaria
/treatmentpolicies.html). Importantly, SP remains the treat-
ment of choice for intermittent preventive treatment of
pregnant women and infants in Africa, both groups being at
major risk for severe disease manifestations of Plasmodium
falciparum malaria (14). Understanding the detailed basis of
resistance to this drug is hence of noteworthy importance.
P. falciparum in vivo and in vitro resistance to py-
rimethamine and sulfadoxine has been well documented to be
associated with point mutations in the respective target genes,
i.e., the P. falciparum dihydrofolate reductase gene (Pfdhfr)
and the P. falciparum dihydropteroate synthase gene (Pfdhps).
In particular, a quintuple mutant (with Pfdhfr mutations
S108N, N51I, and C59R and Pfdhps mutations A437G and
K540E) has been strongly associated with SP treatment failure
(9, 12, 19) on the African continent. However, these genes do
not seem to explain the full mechanism of resistance to SP
(23, 24).
P. falciparum has an endogenous folate biosynthesis path-
way, but most strains can also use exogenous folate through the
folate salvage pathway (17, 23). The influx of exogenous folate
(23) and the proteins responsible for this process (8, 16, 18), as
well as efflux systems able to pump antifolate drugs out of the
parasite intracellular space (16), have been proposed to further
influence antifolate resistance.
In mammalian cells, resistance to antifolates can be medi-
ated through the influx and efflux of folates and antifolates (1).
Multidrug resistance proteins (MRPs) have a central role in
folate and antifolate transport (2). These proteins are mem-
brane transporters that pump xenobiotics and other sub-
stances, e.g., folate (27), out of cells. MRPs have been shown
to mediate antifolate resistance by alteration in the efflux of
drugs, e.g., methotrexate, and folate (10, 21, 27).
In P. falciparum, two MRP homologues, PfMRP1 and
PfMRP2, have been identified (4, 11). PfMRP1 (identification
no. PFA0590w in PlasmoDB [http://plasmodb.org]) has been
suggested previously to have a role in the parasite response to
several antimalarial drugs, including chloroquine and quinine,
through drug efflux (20).
In this work, we hypothesized that an MRP may contribute
to P. falciparum resistance to SP in vivo. This possibility was
tested by examining the genotypes associated with the I876V
and K1466R mutations, previously identified as the most fre-
quent Pfmrp1 polymorphisms in Africa (6), in blood samples
collected from patients pre- and posttreatment in a clinical
efficacy study conducted in Tanzania. The selection of a
Pfmrp1 single nucleotide polymorphism (SNP) upon SP treat-
ment would suggest an involvement of the encoded protein in
the parasite in vivo response to antimalarial drugs. Polymor-
phisms in Pfdhfr and Pfdhps were analyzed as part of a surveil-
lance study for the SP drug, with the results also serving as a
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control for in vivo SP-driven SNP selection in the present
study. The present work is an integrated part of an ongoing
global molecular epidemiology project on the association of
Pfmrp1 diversity and in vivo responses to antimalarial drugs.
MATERIALS AND METHODS
Study subjects. We analyzed P. falciparum-positive blood samples from pa-
tients participating in a clinical trial conducted in Fukayosi, Bagamoyo District,
Coast Region, Tanzania, comparing SP (Fansidar; Roche) with artemether-
lumefantrine (Coartem; Novartis, Basel, Switzerland) during the period from
April to July 2004 (13). In brief, 106 children with microscopically confirmed
acute uncomplicated P. falciparum malaria were enrolled and randomly allocated
to receive standard treatment with SP (n  56) or artemether-lumefantrine (n 
50) according to body weight. After enrolment, the children were followed up
with and checked for parasitemia routinely on days 1, 2, 3, 7, 14, 21, 28, 35, and
42 of the study or on any day of recurrent illness. Blood samples were collected
on filter paper (3MM; Whatman) for molecular genotyping. Informed consent
was obtained from the enrolled children’s parents or guardians. The study was
approved by the ethics committees at the Muhimbili University College of
Health Sciences, Tanzania, and Karolinska Institutet, Sweden.
For the present study, samples from the entire baseline population prior to
drug administration (day 0 [D0]; n  106) and the 40 children in the SP arm of
the study with recurrent infections detected were analyzed. The analysis was
based on previous Pfmsp2 and Pfmsp1 stepwise genotyping to define the recur-
rent parasitemias as either reinfections (new infections) or recrudescences (treat-
ment failures) (13). A recurrent infection was classified as a recrudescence if
there was at least one allelic band for both genetic markers matching with that
in the corresponding D0 sample or as a reinfection if there was no matching
allelic band for at least one genetic marker (13).
DNA extraction. P. falciparum genomic DNA from the clinical trial patients
was extracted from filter paper using an ABI PRISM 6100 nucleic acid prep
station (Applied Biosystems, Fresno, CA) as described previously (5) and frozen
at 20°C until use.
Pfmrp1 I876V and K1466R SNP pyrosequencing. The polymorphic nucleotide
positions 2626 and 4397 (corresponding to amino acid positions 876 and 1466,
respectively) in Pfmrp1 were analyzed by pyrosequencing. The pyrosequencing
protocol and primers were designed with Pyrosequencing assay design software,
version 1.0 (Biotage AB, Uppsala, Sweden). A first PCR amplification was
performed for nucleotide 2626 with the primers A2626G First fw and A2626G
First rev, resulting in a product of 208 bp, and for nucleotide 4397 with A4397G
First fw and A4397G First rev, resulting in a product of 1,176 bp (Table 1). The
nested PCR amplification was performed with primers A2626G Nest fw and
A2626G Nest rev for 2626, giving a 104-bp product, and A4397G Nest fw and
A4397G Nest rev for 4397, giving a 436-bp product. Streptavidin Sepharose
beads (Amersham Biosciences, Little Chalfont, United Kingdom) were added to
the PCR products, and single-stranded biotinylated PCR products were obtained
with a pyrosequencing vacuum prep workstation (Biotage AB, Uppsala, Swe-
den). Pyrosequencing reactions with the primers A2626G Seq rev for nucleotide
position 2626 and A4397G Seq fw for position 4397 were performed using the
PSQ 96 SNP reagent kit and a PyroMark ID instrument according to the rec-
ommendations of the manufacturer (Biotage AB, Uppsala, Sweden). The nucle-
otide dispensation orders were GATACTGAT for 2626 and CGACGATGT for
4397.
Pfdhfr and Pfdhps genotyping. The genotypes for Pfdhfr N51I, C59R, and
S108N/T SNPs were determined through PCR-restriction fragment length poly-
morphism analysis as described by Veiga and colleagues (26), while the analysis
of G437A and K540E SNPs in Pfdhps was performed according to the method of
Duraisingh and colleagues (7) with minor modifications. All restricted products
were visualized on 2% agarose gels (with 0.1 g/ml ethidium bromide) and
analyzed under UV light by using the Bio-Rad Gel Doc 2000 system. The
algorithm from Kublin and colleagues (12) was used to define the Pfdhfr and
Pfdhps haplotypes.
Bioinformatic and statistical analyses. The SNP software PSQTM96MA
(Biotage AB, Uppsala, Sweden) was used to analyze the output from the Pyro-
Mark ID instrument (Biotage AB, Uppsala, Sweden). Fisher’s two-tailed test was
used to evaluate the difference in genotype frequencies between baseline samples
and samples from the times of infection recurrence. Statistical significance was
defined by a P value of 0.05. To test for an association between the quintuple
mutant haplotype and variation in amino acid 1466, the 2 test was used. Samples
with a negative result for either or both of the parameters were excluded. Mixed
genotypes for position 1466 were counted as a K-encoding genotype. These
statistical analyses were performed with GraphPad QuickCalcs (http://www
.graphpad.com). Associations between genotype in baseline samples and recru-
descent outcome were evaluated using odds ratios (OR), and the analyses were
performed with JavaStat (http://statpages.org/ctab2x2.html).
RESULTS
Forty (71%) of 56 children in the SP arm had recurrent
parasitemia during follow-up (13). Pfmsp2 and Pfmsp1 diver-
sity analysis of D0 samples versus samples from the times of
infection recurrence identified 15 recrudescences, 23 reinfec-
tions, and 2 inconclusive outcomes among the 40 recurrences.
To test if Pfdhfr, Pfdhps, and Pfmrp1 were under SP selection
pressure, the frequencies of SNPs in these genes at D0 and at
the times of the recrudescences and reinfections were com-
pared. For Pfmrp1, there was statistically significant selection
of the pure 1466K allele among the samples from children with
recrudescences, of which 12 of 12 (100%) carried the allele,
compared to 52 (67.5%) of 77 baseline samples (P  0.017;
Fisher’s two-tailed test), when samples from subjects with
mixed infections were excluded. This selection was confirmed
by including the mixed infections, counted as corresponding to
either 1466K (P  0.038; Fisher’s two-tailed test) or 1466R
(P  0.020; Fisher’s two-tailed test) (Table 2). Consequently,
the pure 1466R allele that was found in 25 (32.5%) of 77
baseline samples was not detectable in the samples from pa-
tients with recrudescences. Among the samples from children
with reinfections, there were no statistically significant changes
in the frequency of the 1466K allele. There was an association
between the carriage of the 1466K genotype at baseline and
the recrudescence outcome (OR  5.50; 95% confidence in-
terval, 0.81 to 35.66), although it was not statistically signifi-
cant. There were no statistically significant changes in the fre-
quency of the I876I/V SNP (Table 2).
At the baseline, the Pfdhfr Pfdhps quintuple mutant haplo-
type was found in 20 of 96 samples, giving a prevalence of
20.8%. Upon SP therapy, statistically significant selection of
this haplotype, among both 14 (93.3%) of 15 subjects with
recrudescences (P  0.001; Fisher’s two-tailed test) and 17
(77.3%) of 22 subjects with reinfections (P  0.002; Fisher’s
two-tailed test), was observed (Table 2). The presence of the
quintuple mutant haplotype at baseline was associated with
treatment failure (OR  8.25; 95% confidence interval, 2.21 to
31.00).
No association between the quintuple mutation and 1466K
either in the recurrent infections (2  2.210; degrees of free-
dom  3; P  0.5301) or at baseline (2  0.004; degrees of
TABLE 1. Primers for Pfmrp1 PCR and pyrosequencing
Primer name Sequence (533)
A2626G First fw .........AATATTCCATTCAATGAAAATTAC
A2626G First rev ........CAACGTACTTTTATTCATTGAGA
A2626G Nest fw .........Biotin-TATTCCATTCAATGAAAATTACCT
A2626G Nest rev ........TATGGAAGGATCTAAAGATGTAAA
A2626G Seq rev..........GGAAGGATCTAAAGATGTAA
A4397G First fw .........AATAAAGAACATTCAGACACAAT
A4397G First rev ........TGATTTTCCTACTATCCCAATT
A4397G Nest fw .........TGGATACTGTATATCGTTTTCTGC
A4397G Nest rev ........Biotin-CCCAATTTTTTGATTTTTTAAAGC
A4397G Seq fw ...........TGATTATACTCACATAGAAA
2554 DAHLSTRÖM ET AL. ANTIMICROB. AGENTS CHEMOTHER.







freedom  3; P  0.9999) was seen, suggesting independent
selections.
DISCUSSION
SP is still widely used for the treatment of uncomplicated P.
falciparum malaria, particularly in combination with artesunate
or amodiaquine. A remaining key indication for this drug is
intermittent preventive treatment for pregnant women and
infants in Africa. Improved understanding of the molecular
basis of parasite resistance to antifolate drugs is therefore of
major importance.
Point mutations in the genes coding for P. falciparum dihy-
drofolate reductase (PfDHFR) and dihydropteroate synthase
have long been known to be a main mechanism of P. falcipa-
rum resistance against SP. In accordance, we have observed
significant selection of the Pfdhfr Pfdhps quintuple mutant hap-
lotype in recrudescences and reinfections after SP treatment.
Furthermore, there was a significant association between the
presence of the quintuple mutant haplotype at baseline and
subsequent treatment failure, consistent with data in previous
reports (9, 12, 19), pointing to the value of using this haplotype
as an in vivo marker of SP resistance.
However, the likelihood that SP action and resistance in-
volve factors beyond Pfdhfr and Pfdhps has been discussed
previously (23, 24). Herein, we describe the selection of
PfMRP1 1466K among parasites in recrudescent infections
after SP treatment. Importantly, there was no association be-
tween the 1466K SNP and the Pfdhfr Pfdhps quintuple muta-
tion, indicating that 1466K is selected independently of the
quintuple mutant haplotype. Our data suggest that the 1466
genotype at baseline may be related to treatment outcome,
although the results of the analysis were not statistically sig-
nificant, due probably to the small sample size, which was
reflected in the large confidence intervals.
MRPs are frequently involved in the efflux of therapeutic
drugs in various organisms, e.g., chloroquine and quinine in P.
falciparum (20) and the antifolate methotrexate in mammals
(10, 27). However, this mechanism is unlikely to explain the
herein-described selection by SP since these particular antifo-
lates are not organic anions, the typical MRP substrates, and
hence probably not transported by MRPs. Instead, PfMRP1
may affect intracellular folate homeostasis in parasites, as pro-
posed previously for higher eukaryotes (2, 3). In P. falciparum,
the intracellular folate concentration is important for the ac-
tivities of antifolates. This concentration depends on input
from the de novo synthesis of folate and influx through the
folate salvage pathway and output through folate efflux from
the cell. It has been shown previously that increasing folate
levels can impair the effects of antifolate drugs on P. falciparum
in vitro (15, 23) and in vivo (22). These observations are ap-
plied in vitro to modify protocols for the determination of
parasite sensitivity to SP (25). Further studies have shown that
probenecid can reverse P. falciparum resistance to several an-
tifolates, including sulfadoxine and pyrimethamine, due to the
reduction of folate influx into both red blood cells and para-
sites (8, 16, 18).
In mammalian cells, MRPs have a role in folate homeostasis
and have been shown to transport folate out of the cell (3, 27).
The Chinese hamster ovary cell line selected for py-
rimethamine resistance has impaired folate export due to the
repression of MRP genes, resulting in a significant increase in
the intracellular concentrations of folates (21). An expansion
of the folate pool results in the accumulation of dihydrofolate,
the natural substrate of DHFR, if the enzyme is inhibited
by pyrimethamine. Dihydrofolate will compete with py-
rimethamine in binding to DHFR, decreasing the inhibition of
DHFR and resulting in pyrimethamine resistance (2). In this
context, we suggest that PfMRP1 is a putative parasite folate
efflux mechanism, with the 1466R-carrying protein hypotheti-
cally being more effective in this function. In a population
TABLE 2. Prevalence of Pfmrp1 genotypes for amino acid positions 876 and 1466 and Pfdhfr Pfdhps haplotypes in P. falciparum infections at
baseline (D0) and at times of recurrent parasitemia after SP treatment
Gene(s) and amino acid encoded
or haplotype description
No. of positive samples/total no. of samples successfully tested (ratio)a at:
D0d Time of recrudescence Time of reinfection
Pfmrp1
1466K 52/101 (0.515) 12/14 (0.857)* 14/21 (0.667)
1466R 25/101 (0.248) 0/14 (0.000)* 2/21 (0.095)
1466K/R 24/101 (0.238) 2/14 (0.143) 5/21 (0.238)
876I 75/104 (0.721) 12/13 (0.923) 18/23 (0.783)
876V 13/104 (0.125) 1/13 (0.077) 2/23 (0.087)
876I/V 16/104 (0.154) 0/13 (0.000) 3/23 (0.130)
Pfdhfr and Pfdhpsb
Wild type 3/96 (0.031) 0/15 (0.000) 0/22 (0.000)
Single mutant 1/96 (0.010) 0/15 (0.000) 0/22 (0.000)
Double mutant 21/96 (0.219) 0/15 (0.000) 1/22 (0.046)
Triple mutant 36/96 (0.375) 1/15 (0.067) 0/22 (0.048)
Quadruple mutant 15/96 (0.157) 0/15 (0.000) 4/22 (0.182)
Quintuple mutantc 20 (3  17)/96 (0.208) 14 (0  14)/15 (0.933)** 17 (3  14)/22 (0.773)*
a , P  0.05;, P  0.001. Fisher’s exact two-tailed test was used to evaluate if there was a difference in SNP prevalence between the baseline and the recrudescence
and reinfection samples.
b Pfdhfr Pfdhps haplotypes were defined according to the nomenclature proposed by Kublin and colleagues (12).
c The numbers of samples with mixed and pure quintuple mutants (mixed  pure), respectively, are shown.
d The frequencies prior to the administration of the drug at D0 are based on samples from all of the patients enrolled in the study, independent of which treatment
arm they were allocated to.
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exposed to SP, this enhanced capacity would turn out to be a
disadvantage by reducing the intraparasite folate pool and,
consequently, decreasing the competition with the incoming
drugs for their targets. The less active 1466K-harboring pro-
teins would better counteract the actions of the drugs than the
1466R-harboring proteins by allowing increased intracellular
accumulation of folates, which may explain the selection of the
1466K allele upon SP exposure.
In conclusion, our data (i) provide, for the first time, clinical
evidence for the possibility that a P. falciparum MRP homo-
logue contributes to antifolate resistance and (ii) support the
previously reported importance of the Pfdhfr Pfdhps quintuple
mutation in P. falciparum resistance to SP treatment.
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